)
Starlynn Clarke
Director, Preclinical Biology,
Rondo Therapeutics
Dr. Starlynn Clarke is the Director of Preclinical Biology at Rondo Therapeutics, where she leads efforts in developing bispecific antibodies for solid tumor immunotherapy. With extensive experience in drug discovery and development from her previous roles at Frontier Medicines, she has made significant contributions to oncology and immunology programs. Dr. Clarke holds a Ph.D. in Biochemistry and Molecular Biology from UCSF, where her research focused on viral and fungal pathogen proteases. She also has teaching experience as an adjunct faculty member at the University of San Francisco. Her leadership at Rondo Therapeutics is characterized by a strong commitment to advancing cancer immunotherapies.